Cheryl  Pegus net worth and biography

Cheryl Pegus Biography and Net Worth

Director of Boston Scientific

Dr. Cheryl Pegus has been a director of Boston Scientific since May 2024. Dr. Pegus is the Board Chair and Chief Executive Officer of FlyteHealth, a leader in cardiometabolic care. Prior to FlyteHealth, she served as a partner at Morgan Health, where, from November 2022 to May 2024, Dr. Pegus supported the organization’s strategic investments and broader efforts to improve the quality and affordability of employer-sponsored health care. Dr. Pegus is President of Caluent, LLC, a healthcare analytics and advisory company she has owned since 2012. Dr. Pegus previously served as Executive Vice President of Health & Wellness for Walmart from December 2020 through March 2023, where she led the company’s health care businesses and served as a senior advisor. Prior to that, Dr. Pegus served as Chief Medical Officer and President of Consumer Health Solutions for Cambia Health Solutions from September 2018 to December 2020. Dr. Pegus also served as the first Chief Medical Officer of Walgreens from 2010 to 2013, and from 2007 to 2010, as general manager and Chief Medical Officer of SymCare Personalized Health Solutions, Inc., a diabetes-focused division of Johnson & Johnson. Prior to that, Dr. Pegus served as a medical director at Aetna and Pfizer. She began her career in private practice as a cardiologist. Dr. Pegus is currently a member of the board of directors of Concentra Group Holdings Parent, Inc. (known as “Concentra”), a provider of occupational health services. Dr. Pegus is co-founder of A New Beat, an organization focused on advancing cardiovascular health and supporting the career growth of emerging leaders in the field of cardiology, and currently serves on the boards of private organizations, including the American Heart Association. Dr. Pegus previously served as a director of several public companies, including Phreesia, Inc., Tactile Systems Technology, Inc. and Cogentix Medical, Inc. Dr. Pegus received an MD from Weill Cornell Medical College, an MPH from Columbia University Mailman School of Public Health, and a BA from Brandeis University.

What is Cheryl Pegus' net worth?

The estimated net worth of Cheryl Pegus is at least $102.04 thousand as of May 20th, 2026. Dr. Pegus owns 1,770 shares of Boston Scientific stock worth more than $102,041 as of May 27th. This net worth approximation does not reflect any other assets that Dr. Pegus may own. Learn More about Cheryl Pegus' net worth.

How do I contact Cheryl Pegus?

The corporate mailing address for Dr. Pegus and other Boston Scientific executives is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. Boston Scientific can also be reached via phone at (508) 683-4000 and via email at [email protected]. Learn More on Cheryl Pegus' contact information.

Has Cheryl Pegus been buying or selling shares of Boston Scientific?

Within the last three months, Cheryl Pegus has bought $99,987.30 in shares of Boston Scientific stock. Most recently, on Wednesday, May 20th, Cheryl Pegus bought 1,770 shares of Boston Scientific stock. The stock was acquired at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director now directly owns 1,770 shares of the company's stock, valued at $99,987.30. Learn More on Cheryl Pegus' trading history.

Who are Boston Scientific's active insiders?

Boston Scientific's insider roster includes Kevin Ballinger (EVP), Supratim Bose (EVP), Daniel Brennan (CFO), Vance Brown (SVP), Arthur Butcher (EVP), Wendy Carruthers (SVP), Nelda Connors (Director), Keith Dawkins (EVP), Charles Dockendorff (Director), Jodi Eddy (SVP), Joseph Fitzgerald (EVP), Yoshiaki Fujimori (Director), David Habiger (Director), Edward Ludwig (Director), Edward Ludwig (Director), Edward Mackey (EVP), Michael Mahoney (CEO), Ian Meredith (EVP), Jeffrey Mirviss (EVP), Jonathan Monson (CAO), Maulik Nanavaty (SVP), Scott Olson (SVP), Cheryl Pegus (Director), Michael Phalen (EVP), David Pierce (EVP), Timothy Pratt (EVP), Desiree Ralls-Morrison (SVP), Meghan Scanlon (SVP), John Sorenson (SVP), Eric Thepaut (EVP), Xin Wang (SVP), David Wichmann (Director), and Ellen Zane (Director). Learn More on Boston Scientific's active insiders.

Are insiders buying or selling shares of Boston Scientific?

During the last twelve months, Boston Scientific insiders bought shares 4 times. They purchased a total of 9,800 shares worth more than $554,011.70. During the last twelve months, insiders at the medical equipment provider sold shares 15 times. They sold a total of 699,025 shares worth more than $70,519,687.27. The most recent insider tranaction occured on May, 20th when Director Cheryl Pegus bought 1,770 shares worth more than $99,987.30. Insiders at Boston Scientific own 0.3% of the company. Learn More about insider trades at Boston Scientific.

Information on this page was last updated on 5/20/2026.

Cheryl Pegus Insider Trading History at Boston Scientific

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2026Buy1,770$56.49$99,987.301,770View SEC Filing Icon  
See Full Table

Cheryl Pegus Buying and Selling Activity at Boston Scientific

This chart shows Cheryl Pegus's buying and selling at Boston Scientific by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Boston Scientific Company Overview

Boston Scientific logo
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $50.99
Low: $51.46
High: $53.20

50 Day Range

MA: $61.52
Low: $52.67
High: $71.29

2 Week Range

Now: $50.99
Low: $51.46
High: $109.50

Volume

4,148,400 shs

Average Volume

16,390,297 shs

Market Capitalization

$75.78 billion

P/E Ratio

21.35

Dividend Yield

N/A

Beta

0.62